Introduction
Flortaucipir, also known as [
F]-AV-1451 or [
18 F]-T807, has been shown to detect cortical tau pathology in the form of neurofibrillary tangles, in increasing amounts over the spectrum from healthy aging, mild cognitive impairment, and Alzheimer's disease [1] [2] [3] [4] . The tracer, however, also displays age-related off-target binding of unclear origin in the basal ganglia and to neuromelanin-rich cells of the substantia nigra and retina [5] [6] [7] . Another tau-tracer, [ 18 F]THK-5351, with a similar uptake pattern to flortaucipir at a macroscopic level, was recently shown to be a substrate for monoamine oxidase type B (MAO-B) in vivo and in autoradiography, and its binding was blocked by the MAO-B inhibitor selegiline [8] . Interestingly, positron emission tomography (PET) scans with the MAO-B marker [ 11 C]deprenyl [9] show similarities with [ 18 F]THK-5351 and flortaucipir PET scans. Further, brain MAO-B is known to increase with age [10] . It is, therefore, conceivable that MAO-B is also a target of flortaucipir.
We have previously reported on the flortaucipir-binding pattern of a group of patients with Parkinson's disease [5, 11] . Fifty-nine percent of these tau negative patients who had flortaucipir PET had received MAO-B inhibitors within 24 h of their scan, as we were unaware at that time of the possible influence of MAO-B activity on flortaucipir binding. With the purpose of investigating the validity of our previous studies and for future reference in clinical use, we retrospectively investigated if MAO-B inhibitor use in clinical doses affects flortaucipir binding.
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Materials and Methods
Twenty-seven Parkinson's disease patients who have been previously described [5, 11] were retrospectively stratified based on their MAO-B inhibitor use based on their lists of medication at the time of the flortaucipir scan [5] . The study was approved by the regional ethics committee, and all subjects signed an informed consent form. Scan coregistration, volume of interest definition, and data extraction were performed with PMOD software (PMOD, Zürich, Switzerland), as previously described [5] .
Regional statistical analysis was performed with Stata 13.1(StataCorp LP, Texas). Voxel-wise analyses were performed with SPM12 (http://www.fil.ion.ucl.ac.uk/spm/), using a linear regression model with standardized uptake values as the dependent variable and group and age as independent variables. Family-wise error corrections were used for voxel-wise analyses. Continuous and categorical variables were interrogated using Student's t test and Fisher's exact test, respectively. P values G 0.05 were considered statistically significant.
Results
Six of 27 Parkinson's disease patients reported taking selegiline (one 5 mg, four 10 mg, and one 15 mg per day), and ten other patients reported taking rasagiline (all 1 mg per day) on the day of scan. See Table 1 for demographics.
No significant between group differences in mean flortaucipir uptake was seen in regional ( Fig. 1 ) or voxelwise analyses (Fig. 2) . A more liberal, explorative approach with simple inspection of t-maps revealed no meaningful trends in group differences.
Discussion
Our results suggest that flortaucipir PET is not significantly affected by oral ingestion of MAO-B inhibitors at clinically prescribed doses. It therefore seems unlikely that MAO-B binding is contributing to the basal ganglia signal seen in flortaucipir PET images. However, we cannot rule out noncompetitive binding of flortaucipir to a different binding site on MAO-B, which may be unaffected by the MAO-B inhibitors in clinical use.
In an early paper on flortaucipir (then known as [ 18 F]T807), Xia et al. [12] found that Bno inhibition was seen for MAO-A and MAO-B at a 1-μM concentration.^This was specifically tested, as the group of compounds the tracer belongs to, the carbazoles, was found to contain potent MAO inhibitors. Later, in a conference presentation, Vermeiren and colleagues reported affinity of flortaucipir for MAO-A (K D ≈ 1.5 nM) and MAO-B (K D ≈ 30 nM) [13] , though this has not to our knowledge been published in detail. Several unsuccessful attempts have been made to identify other targets using autoradiography [6, 7, 14, 15] . [17] . Further, the binding of these three tracers all extend to include cortical areas in Alzheimer's disease (flortaucipir [1] , [ 18 F]THK-5351 [18] , and C-11 labeled selegiline (L-[
11 C]-deuterium-deprenyl) [9] ). One notable exception to this pattern is that flortaucipir has additional off-target binding in the substantia nigra [7] , presumed to be neuromelanin, and also to the choroid plexus [19] . The similar brain distributions of flortaucipir uptake and MAO-B activity and the age dependency of both suggest the possibility of significant MAO-B binding by flortaucipir [10] . Also, the paradoxical pattern of flortaucipir PET in progressive supranuclear palsy patients, with an absence of binding in cortex but increased binding in the basal ganglia compared with healthy controls, could be compatible with MAO-B binding of this agent [6, 16, [20] [21] [22] . The observations in progressive supranuclear palsy may be explained by increased amounts of MAO-B from associated gliosis, rather than binding to the 4-repeat tau present. The linear tau seen in progressive supranuclear palsy has been autoradiographically shown to have a low affinity for flortaucipir as compared to the mixed 3 and 4 repeat paired helical tau of Alzheimer's disease [7, 14] . Further, the unexplained increased flortaucipir binding in the putamen of multiple system atrophy [23] could also be attributable to concomitant gliosis and raised MAO-B. Indeed, Shcherbinin et al. reported findings suggesting Beither additional off-target binding in the putamen or a second binding site with different kinetics^ [24] . We have previously reported reduced off-target flortaucipir binding in the substantia nigra of Parkinson's disease [5] , compatible with a decrease in neuromelanin content [25] . While similar pigment-like compounds increasing with age have been described in the basal ganglia [26] , Passamonti and colleagues found no neuromelanin-containing cells in the basal ganglia in patients or controls with relatively increased in vivo flortaucipir PET binding in the same area [6] . If MAO-B is a significant target of flortaucipir at levels used for in vivo PET, it diminishes the tracer's value as a marker of tau and an outcome measure in pharmaceutical trials. Further, as brain MAO-B (and -A) is reduced by smoking [27] , present smoking status would have to be recorded for clinical use. As MAO-B appears to be a significant target of [ According to Vermeiren et al. [13] and the investigator's brochure, flortaucipir displays higher affinity for MAO-A than MAO-B [13] . This affinity for MAO-A may be less problematic as MAO-A occurs in lower concentration and does not show age-dependent increases [10] . Further, the increase of MAO activity from astrocytes observed in Alzheimer's disease appears to be due to increased MAO-B activity alone [28] . To our knowledge, no attempts have been made to block flortaucipir signal using the MAO-A inhibitor clorgyline. Clorgyline can, however, be used as a PET-tracer and shows a pattern of high binding in the thalamus and occipital cortex, intermediate values in basal ganglia, frontal, and temporal cortices, and little binding in the cerebellum [29, 30] . Another MAO-A tracer, [ 11 C]harmine [31] , displays a similar pattern [32] . Hence, the binding pattern of these MAO-A tracers does not appear to match the pattern shown by flortaucipir.
This study has several limitations. First, we did not have paired blocked and unblocked patient data. However, Ng et al. showed robust [ [33, 34] . Consequently, the impact of a patient having missed a single or even two doses before scan would be negligible. Third, the use of chronic administration in our study, rather than acute treatment as in Ng et al. may cause unforeseen effects, including compensatory regulation of the MAO-A and -B enzymes, which could ultimately affect the results. Fourth, two different MAO-B inhibitors with different structures and metabolites were used. Considering the large effect size described by Ng et al., we would expect to see at least a bimodal distribution in the MAO-B inhibitor group, even if only selegiline and not rasagiline was an effective blocker of flortaucipir binding. Finally, as none of our Parkinson's disease patients appeared to be tau-positive, we were unable to investigate if the specific binding from areas with neurofibrillary tangles was blockable with MAO-B inhibitors [9, 35] .
Conclusion
Several observations from human PET studies suggest that MAO-B as well as tau could be a target of flortaucipir binding. However, after retrospectively comparing Parkinson's disease patients receiving clinical doses of MAO-B inhibitors with those who did not, we were unable to detect any significant effect of MAO-B inhibition on flortaucipir uptake. Further studies are needed to investigate the origin of the off-target binding of flortaucipir.
